Selection of this agent requires careful consideration and discussion between the clinician and patient about (1) the biology of the patient's disease, (2) the toxicity of the agent and risks to the patient compared with other standardly available agents, and (3) the cost of the agent and insurance coverage.
The standard-of-care treatment for first-line metastatic TNBC with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of 10 or more is chemotherapy plus pembrolizumab.
This was evaluated in the KEYNOTE-355 trial.[56,57] The phase III, randomized, placebo-controlled, double-blind, multinationalKEYNOTE-355trial (NCT02819518) evaluated the addition of pembrolizumab to first-line chemotherapy in patients with metastatic TNBC.